Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review
Visceral leishmaniasis (VL), also known as Kala-azar, is caused by Leishmania (L.) donovani complex, which includes L. donovani and L. infantum and is associated with a high death rate as compared to the cutaneous and subcutaneous form. Treatment of VL includes chemotherapeutic agents which are asso...
Published in: | Asian Pacific Journal of Tropical Medicine |
---|---|
Main Authors: | , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2022
|
Subjects: | |
Online Access: | https://doi.org/10.4103/1995-7645.348156 https://doaj.org/article/ba9ebd244fc64526a063852cb1d45445 |
id |
ftdoajarticles:oai:doaj.org/article:ba9ebd244fc64526a063852cb1d45445 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:ba9ebd244fc64526a063852cb1d45445 2023-05-15T15:06:29+02:00 Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review Soumya Ranjan Satapathy Rudra Narayan Sahoo 2022-01-01T00:00:00Z https://doi.org/10.4103/1995-7645.348156 https://doaj.org/article/ba9ebd244fc64526a063852cb1d45445 EN eng Wolters Kluwer Medknow Publications http://www.apjtm.org/article.asp?issn=1995-7645;year=2022;volume=15;issue=7;spage=293;epage=307;aulast=Satapathy https://doaj.org/toc/2352-4146 2352-4146 doi:10.4103/1995-7645.348156 https://doaj.org/article/ba9ebd244fc64526a063852cb1d45445 Asian Pacific Journal of Tropical Medicine, Vol 15, Iss 7, Pp 293-307 (2022) visceral leishmaniasis doxorubicin passive targeting repositioning non-pegylated liposome encapsulated doxorubicin resistance Arctic medicine. Tropical medicine RC955-962 article 2022 ftdoajarticles https://doi.org/10.4103/1995-7645.348156 2022-12-31T00:29:21Z Visceral leishmaniasis (VL), also known as Kala-azar, is caused by Leishmania (L.) donovani complex, which includes L. donovani and L. infantum and is associated with a high death rate as compared to the cutaneous and subcutaneous form. Treatment of VL includes chemotherapeutic agents which are associated with some major hurdles like toxicities, parenteral administration, high cost, parasite resistance and stability. Hence, there is an urgent requirement to develop novel chemotherapeutic agents or repurposing of existing drugs against VL. Developing formulation of new chemical entity for the treatment of VL is laborious, time consuming and associated with huge financial burden. However, screening of existing chemotherapeutic agents is a good alternative to avail cost-effective treatment option for VL. Non-PEGylated liposome encapsulated doxorubicin (Myocet®) is proposed as an alternative treatment option for VL in this review article. Here, we covered the fundamental aspects of VL, loophole associated with available current treatment strategies and non-PEGylated liposome encapsulated doxorubicin as a novel alternative formulation for treating VL, as this liposomal delivery system of doxorubicin might passively target the intra- cellular regions of macrophage. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Azar ENVELOPE(-63.733,-63.733,-64.983,-64.983) Asian Pacific Journal of Tropical Medicine 15 7 293 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
visceral leishmaniasis doxorubicin passive targeting repositioning non-pegylated liposome encapsulated doxorubicin resistance Arctic medicine. Tropical medicine RC955-962 |
spellingShingle |
visceral leishmaniasis doxorubicin passive targeting repositioning non-pegylated liposome encapsulated doxorubicin resistance Arctic medicine. Tropical medicine RC955-962 Soumya Ranjan Satapathy Rudra Narayan Sahoo Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review |
topic_facet |
visceral leishmaniasis doxorubicin passive targeting repositioning non-pegylated liposome encapsulated doxorubicin resistance Arctic medicine. Tropical medicine RC955-962 |
description |
Visceral leishmaniasis (VL), also known as Kala-azar, is caused by Leishmania (L.) donovani complex, which includes L. donovani and L. infantum and is associated with a high death rate as compared to the cutaneous and subcutaneous form. Treatment of VL includes chemotherapeutic agents which are associated with some major hurdles like toxicities, parenteral administration, high cost, parasite resistance and stability. Hence, there is an urgent requirement to develop novel chemotherapeutic agents or repurposing of existing drugs against VL. Developing formulation of new chemical entity for the treatment of VL is laborious, time consuming and associated with huge financial burden. However, screening of existing chemotherapeutic agents is a good alternative to avail cost-effective treatment option for VL. Non-PEGylated liposome encapsulated doxorubicin (Myocet®) is proposed as an alternative treatment option for VL in this review article. Here, we covered the fundamental aspects of VL, loophole associated with available current treatment strategies and non-PEGylated liposome encapsulated doxorubicin as a novel alternative formulation for treating VL, as this liposomal delivery system of doxorubicin might passively target the intra- cellular regions of macrophage. |
format |
Article in Journal/Newspaper |
author |
Soumya Ranjan Satapathy Rudra Narayan Sahoo |
author_facet |
Soumya Ranjan Satapathy Rudra Narayan Sahoo |
author_sort |
Soumya Ranjan Satapathy |
title |
Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review |
title_short |
Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review |
title_full |
Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review |
title_fullStr |
Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review |
title_full_unstemmed |
Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review |
title_sort |
conventional treatments and non-pegylated liposome encapsulated doxorubicin for visceral leishmaniasis: a scoping review |
publisher |
Wolters Kluwer Medknow Publications |
publishDate |
2022 |
url |
https://doi.org/10.4103/1995-7645.348156 https://doaj.org/article/ba9ebd244fc64526a063852cb1d45445 |
long_lat |
ENVELOPE(-63.733,-63.733,-64.983,-64.983) |
geographic |
Arctic Azar |
geographic_facet |
Arctic Azar |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Asian Pacific Journal of Tropical Medicine, Vol 15, Iss 7, Pp 293-307 (2022) |
op_relation |
http://www.apjtm.org/article.asp?issn=1995-7645;year=2022;volume=15;issue=7;spage=293;epage=307;aulast=Satapathy https://doaj.org/toc/2352-4146 2352-4146 doi:10.4103/1995-7645.348156 https://doaj.org/article/ba9ebd244fc64526a063852cb1d45445 |
op_doi |
https://doi.org/10.4103/1995-7645.348156 |
container_title |
Asian Pacific Journal of Tropical Medicine |
container_volume |
15 |
container_issue |
7 |
container_start_page |
293 |
_version_ |
1766338088789868544 |